Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
An FDA advisory committee recommended against full approval for Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva by a 13-1 vote, concluding that confirmatory
Arbor Biotechnologies is trimming its early-stage discovery work, leading to layoffs in the group. The move was confirmed by an Arbor spokesperson, with CEO Devyn
The rise and fall of the short-lived biotech Zymergen has ended with a $30 million penalty from the SEC. Zymergen’s rise began in April 2021
(This is a preview of Post-Hoc, our latest newsletter with analysis and dispatches from our journalists. To sign up for future editions, Sign up to
Viral disease-focused biotech Atea Pharmaceuticals announced a late-stage trial failure for its nucleotide polymerase inhibitor, which it was investigating as a Covid-19 treatment. The Phase
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Stimulants prescribed during telehealth … Sign up